What Is Selank?
Selank (TP-7) is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is a modified analog of tuftsin, a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) that is cleaved from the Fc region of immunoglobulin G and plays a role in immune modulation. The Selank molecule extends tuftsin's sequence with a Pro-Gly-Pro tripeptide tail, which dramatically improves its metabolic stability and allows it to cross the blood-brain barrier more effectively.
Selank was approved in Russia in 2009 as a prescription anxiolytic and nootropic medication, marketed under the trade name Selanc. It is classified as an anxiolytic peptide with additional nootropic (cognitive-enhancing) properties. Unlike benzodiazepines, Selank does not produce sedation, motor impairment, amnesia, or physical dependence — making it a fundamentally different class of anxiolytic agent.
Mechanism of Action
GABAergic Modulation
The primary anxiolytic mechanism of Selank involves modulation of the gamma-aminobutyric acid (GABA) neurotransmitter system. Research published in Frontiers in Pharmacology demonstrated that Selank can directly influence the expression of genes involved in GABAergic neurotransmission, and its effects are similar to GABA itself, suggesting it works through GABA-A receptors Volkova et al., 2016.
A subsequent study by the same research group found that while Selank does not directly activate the GABAergic system in IMR-32 cell culture, it may modulate the action of other drugs by affecting brain-derived neurotrophic factor (BDNF) expression Filatova et al., 2017. This dual mechanism — both direct GABAergic gene modulation and indirect BDNF-mediated effects — may explain why Selank produces anxiolytic effects without the cognitive impairment associated with direct GABA-A agonists like benzodiazepines.
BDNF and Neuroprotection
Brain-derived neurotrophic factor (BDNF) is a critical protein for neuronal survival, synaptic plasticity, and memory formation. Selank has been shown to protect against ethanol-induced memory impairment by regulating BDNF content in the hippocampus and prefrontal cortex Kolik et al., 2019. This neuroprotective action suggests that Selank may have applications beyond simple anxiolysis — potentially supporting cognitive function under conditions of neurological stress.
Enkephalin System Modulation
Selank also influences the endogenous opioid system, specifically the enkephalin pathway. Research has shown that Selank can stabilize enkephalin levels in the blood, which contributes to its mood-regulating and stress-buffering effects. This mechanism is distinct from both benzodiazepines and SSRIs, positioning Selank as a truly novel anxiolytic with a multi-target pharmacological profile.
Clinical Evidence
Anxiolytic Effects Comparable to Benzodiazepines
The most compelling clinical evidence for Selank comes from comparative studies with established anxiolytic drugs. A landmark study published in Behavioural Neurology demonstrated that the anxiolytic effect of Selank is comparable to that of classical benzodiazepine drugs, and that the basis of their mechanism of action may be similar Kasian et al., 2017. In this study using the unpredictable chronic mild stress (UCMS) model in rats, Selank enhanced the effect of diazepam in reducing anxiety — suggesting potential synergistic effects when combined with low-dose benzodiazepines.
Withdrawal and Dependence Mitigation
A 2022 study in the Bulletin of Experimental Biology and Medicine found that Selank, like diazepam, weakens the aversive signs of morphine withdrawal in rats with opiate dependence Konstantinopolsky et al., 2022. This finding is significant because it suggests Selank may have therapeutic potential in substance use disorders — an area where current pharmacological options are limited.
Cognitive Protection
The neuroprotective properties of Selank extend to protection against substance-induced cognitive damage. Selank prevented ethanol-induced memory and attention disturbances in animal models, with the protective effect linked to its regulation of BDNF content in key brain regions Kolik et al., 2019.
Ready to start a personalized peptide protocol? The licensed providers at Telegenix specialize in peptide therapy and hormone optimization. Book a free consultation to get a protocol tailored to your bloodwork, goals, and biology.
Selank vs. Semax: Understanding the Differences
Selank is frequently compared to Semax, another Russian-developed peptide nootropic. While both are synthetic peptides with nootropic properties, they have distinct pharmacological profiles:
| Feature | Selank | Semax |
|---|---|---|
| Base molecule | Tuftsin analog | ACTH(4-10) analog |
| Primary effect | Anxiolytic + nootropic | Nootropic + neuroprotective |
| Mechanism | GABA modulation, BDNF | Melanocortin receptors, BDNF |
| Best for | Anxiety, stress, calm focus | Focus, memory, cognitive drive |
| Sedation | None | None |
| Immune effects | Immunomodulatory (tuftsin-based) | Minimal |
| Russian approval | Yes (2009) | Yes (2011) |
Many practitioners and researchers note that the two peptides may be complementary — Selank for its calming, anxiolytic properties and Semax for its stimulating, focus-enhancing effects.
Dosing Protocols from Research
Important: The following dosing information is derived from published research protocols and is presented for educational purposes only. Selank is not FDA-approved in the United States.
Intranasal Administration (Most Common)
Research protocols have typically used intranasal administration at doses of 250-500 mcg per nostril, administered 2-3 times daily. The intranasal route provides rapid absorption and direct access to the central nervous system via the olfactory pathway.
Subcutaneous Injection
Some clinical protocols have used subcutaneous injection at doses of 250-750 mcg daily, typically administered once in the morning.
Cycle Length
Research protocols have generally used Selank for periods of 14-30 days, followed by a washout period of equal duration. Unlike benzodiazepines, no tolerance development has been reported in the published literature.
Looking for a supervised peptide or TRT protocol? The clinical team at Telegenix designs evidence-based protocols tailored to your biology. Book a free consultation and stop guessing.
Safety Profile
Selank has demonstrated a remarkably favorable safety profile across multiple studies. Key safety findings include:
No sedation or motor impairment — Unlike benzodiazepines, Selank does not cause drowsiness, coordination problems, or psychomotor slowing. This is a critical advantage for daytime anxiolysis.
No dependence or withdrawal — No physical dependence or withdrawal syndrome has been reported in any published study, even after extended use. This contrasts sharply with benzodiazepines, which can produce severe dependence within weeks.
No cognitive impairment — Rather than impairing cognition (as benzodiazepines do), Selank appears to enhance cognitive function, particularly under conditions of stress or neurological insult.
Minimal side effects — The most commonly reported side effects in clinical studies are mild and transient, including nasal irritation (with intranasal use) and occasional mild headache.
Limitations and Considerations
Despite the promising research, several important limitations should be noted. Most clinical studies have been conducted in Russia, and large-scale, multi-center randomized controlled trials meeting Western regulatory standards (FDA, EMA) have not been completed. The peptide is not FDA-approved and is not available through conventional pharmacies in the United States or European Union. Long-term safety data beyond 30-day treatment cycles is limited. Additionally, as a peptide, Selank requires either intranasal or injectable administration — oral bioavailability is negligible.
Key Takeaways
- Selank is a synthetic tuftsin analog with anxiolytic effects comparable to benzodiazepines, but without sedation, dependence, or cognitive impairment.
- Its mechanism involves GABAergic gene modulation, BDNF regulation, and enkephalin system stabilization — a multi-target approach distinct from any existing anxiolytic drug class.
- Clinical evidence supports its use for generalized anxiety, stress resilience, and cognitive protection, with an excellent safety profile.
- Selank is approved in Russia but not FDA-approved in the United States; most research has been conducted in Russian institutions.
- Google Trends data shows a +3,700% breakout in search interest for Selank in early 2026, reflecting growing public awareness of peptide-based mental health interventions.
References
-
Kasian A, Kolomin T, Andreeva L, et al. "Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats." Behavioural Neurology. 2017;2017:5091027. PubMed: 28280289
-
Konstantinopolsky MA, Chernyakova IV, Kolik LG. "Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats." Bulletin of Experimental Biology and Medicine. 2022;173(6):730-733. PubMed: 36322304
-
Kolik LG, Nadorova AV, Antipova TA, et al. "Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats." Bulletin of Experimental Biology and Medicine. 2019;167(5):641-644. PubMed: 31625062
-
Filatova E, Kasian A, Kolomin T, et al. "GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells." Frontiers in Pharmacology. 2017;8:89. PubMed: 28293190
-
Volkova A, Shadrina M, Kolomin T, et al. "Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission." Frontiers in Pharmacology. 2016;7:31. PubMed: 26924987
This article is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article may not be FDA-approved. Always consult a qualified healthcare provider before starting any new supplement or therapy. OnlinePeptideDoctor.com does not sell peptides or provide medical consultations.
Explore Related Peptides on OnlinePeptideDoctor.com
- Dihexa: Cognitive Enhancement Peptide Research [blocked] — Another nootropic peptide with different mechanisms
- DSIP: The Deep Sleep Peptide [blocked] — Selank's anxiolytic effects pair well with sleep optimization
- Epithalon: Anti-Aging Telomere Research [blocked] — Combine neuroprotection with longevity
- Peptides for Sleep: Complete Guide [blocked] — How peptides can improve sleep architecture
- Browse All Peptide Articles [blocked] — 80+ research-backed articles
